Here at Zacks, we focus on our proven ranking system, which places an emphasis on earnings estimates and estimate revisions, to find winning stocks. But we also understand that investors develop their own strategies, so we are constantly looking at the latest trends in value, growth, and momentum to find strong companies for our readers.Considering these trends, value investing is clearly one of the most preferred ways to find strong stocks in any type of market. Value investors use tried-and-true metrics a ...

The proven Zacks Rank system focuses on earnings estimates and estimate revisions to find winning stocks. Nevertheless, we know that our readers all have their own perspectives, so we are always looking at the latest trends in value, growth, and momentum to find strong picks.Considering these trends, value investing is clearly one of the most preferred ways to find strong stocks in any type of market. Value investors use a variety of methods, including tried-and-true valuation metrics, to find these stocks. ...

Core Insights - Viavi Solutions Inc. has launched a Visual-Aided Inertial Navigation System (VINS) to enhance the navigation capabilities of aircraft and UAVs in the absence of GPS/GNSS signals, addressing the increasing incidents of GPS jamming and spoofing [1][10] Group 1: VINS Technology and Features - VINS utilizes Maxar Raptor 3D vision-based positioning software, allowing UAVs to perform long-range missions under challenging GNSS conditions, achieving horizontal positioning accuracy within 35 meters and vertical accuracy within 5 meters in GNSS-denied environments [3] - When GNSS is active, VINS significantly improves accuracy, offering horizontal positioning within 1 meter and heading accuracy of 0.1 degrees [3] - The system is designed for low-altitude operations and integrates various components, including processing and sensor modules, GNSS or CRPA antennas, and optional features like data transmission radios and M-code GNSS receivers [4][10] Group 2: Market Context and Demand - The U.S. Department of Transportation reports up to 700 GPS jamming incidents globally each day, with conflict zones like Lithuanian airspace experiencing over 800 cases in the last quarter of 2024, impacting communication networks and emergency services [2] - Viavi's recent third-quarter fiscal 2025 results exceeded expectations, driven by strong demand from service providers and network equipment manufacturers, particularly in the wireless and fiber markets [7] Group 3: Future Outlook - For the fourth quarter of fiscal 2025, Viavi anticipates revenues between $278 million and $290 million, with non-GAAP earnings per share projected between 10 cents and 13 cents, although macroeconomic challenges may pose risks [8] - The VINS will be showcased at the 2025 Joint Navigation Conference, highlighting its relevance in military operations and degraded environments [5]

Core Insights - Amgen's Imdelltra (tarlatamab-dlle) shows promising results in treating small cell lung cancer (SCLC), demonstrating a 40% reduction in the risk of death and extending median overall survival by more than five months compared to standard chemotherapy [1][2][5] Clinical Data - The global phase III DeLLphi-304 study reported a median overall survival of 13.6 months for patients treated with Imdelltra, compared to 8.3 months for the control group [3][5] - Imdelltra also exhibited a statistically significant improvement in median progression-free survival compared to standard-of-care chemotherapy [3][5] - The drug was well-tolerated, with most adverse events being mild to moderate in severity [4][5] Market Context - SCLC accounts for approximately 15% of over 2.4 million global lung cancer cases annually, with a low five-year survival rate of 5-10% across all stages [8] - Amgen's stock has increased by 10.7% year-to-date, contrasting with a 3.9% decline in the industry [4] Regulatory Approval - Imdelltra received FDA approval in 2024 for pre-treated extensive-stage SCLC patients under the accelerated approval pathway, marking it as the first DLL3-targeting BiTE therapy [9] - The drug generated sales of $81 million in Q1 2025, reflecting a 21% sequential increase driven by volume growth [10] Future Outlook - Continued approval of Imdelltra is contingent on the success of the ongoing phase III DeLLphi-304 study, which serves as the confirmatory study for the extensive-stage SCLC indication [10]

Key Takeaways RYAAY carried 17.5M passengers in April 2025, marking an 8% rise from the prior year. Ryanair's April load factor declined 200 bps year over year but remained strong at 92%. Traffic outpaced prior months, rising from 15M in March and 12.6M in February 2025.Ryanair (RYAAY) reported solid traffic numbers for April 2025, driven by upbeat air travel demand.The number of passengers transported on Ryanair flights was 17.5 million in April 2025, reflecting an 8% year-over-year increase. RYAAY’s tra ...

Group 1 - Zacks Premium offers various tools for investors to enhance their stock market strategies, including daily updates on Zacks Rank and Industry Rank, Equity Research reports, and Premium stock screens [1][2] - The Zacks Style Scores provide a rating system for stocks based on value, growth, and momentum, helping investors identify securities with high potential for market outperformance [2][3] Group 2 - The Value Score focuses on identifying undervalued stocks using financial ratios such as P/E, PEG, and Price/Cash Flow [3] - The Growth Score assesses a company's financial health and future outlook by analyzing projected and historical earnings, sales, and cash flow [4] - The Momentum Score evaluates stocks based on price trends and earnings estimate changes to identify optimal buying opportunities [5] Group 3 - The VGM Score combines the Value, Growth, and Momentum Scores to highlight stocks with the best overall potential [6] - The Zacks Rank is a proprietary model that utilizes earnings estimate revisions to guide investors in building successful portfolios [7][10] Group 4 - Stocks rated 1 (Strong Buy) have historically produced an average annual return of +25.41% since 1988, significantly outperforming the S&P 500 [8] - Investors are encouraged to select stocks with a Zacks Rank of 1 or 2 and Style Scores of A or B for optimal investment potential [10][11] Group 5 - The Cooper Companies Inc operates globally in the specialty medical device sector, with two segments: CooperVision and CooperSurgical [12] - Currently rated 3 (Hold) with a VGM Score of A, Cooper is projected to achieve year-over-year earnings growth of 9.8% for the current fiscal year [12][13] - Recent upward revisions by analysts have increased the Zacks Consensus Estimate for Cooper to $4.05 per share, with an average earnings surprise of 3.2% [13]

Taking full advantage of the stock market and investing with confidence are common goals for new and old investors, and Zacks Premium offers many different ways to do both.The research service features daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, all of which will help you become a smarter, more confident investor.Zacks Premium also includes the Zacks Style Scores. What are the Zacks Style Scores? The Zack ...

Taking full advantage of the stock market and investing with confidence are common goals for new and old investors, and Zacks Premium offers many different ways to do both.The research service features daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, all of which will help you become a smarter, more confident investor.Zacks Premium includes access to the Zacks Style Scores as well. What are the Zacks Style Sco ...

Core Insights - The Phase 3 AMPLITUDE study demonstrates the efficacy of the combination of niraparib and abiraterone acetate in delaying cancer progression and symptom worsening in patients with metastatic hormone-sensitive prostate cancer (mHSPC) with homologous recombination repair (HRR) genetic alterations, particularly BRCA [1][2][3] Study Results - The study involved 696 patients and met its primary endpoint of radiographic progression-free survival (rPFS), showing a nearly 50% reduction in disease progression for patients with BRCA alterations, with a hazard ratio (HR) of 0.52 [1][3] - Patients with any HRR alteration also benefited, with a 37% reduction in risk of progression (HR 0.63) [1] - The combination treatment reduced the risk of symptomatic progression by 56% in BRCA patients and 50% in all HRR-altered patients [1] Clinical Implications - Approximately 25% of mHSPC patients have HRR alterations, with BRCA mutations leading to faster disease progression and poorer outcomes [1][2] - The AMPLITUDE trial is the first to show clinical improvement with a PARP inhibitor-based combination in mHSPC, suggesting a new treatment option for these patients [1][2] Safety Profile - Grade 3/4 adverse events were more frequent in the niraparib combination group (75% vs. 59% in placebo), but treatment discontinuations due to adverse events remained low [1][3] Future Directions - The findings highlight the need for early initiation of personalized treatment strategies for patients with mHSPC and HRR alterations, particularly BRCA [1][2]

Core Insights - Johnson & Johnson announced significant findings from two Phase 3 studies demonstrating that DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) based regimens lead to deep and sustained minimal residual disease (MRD) negativity and improved long-term progression-free survival (PFS) in newly diagnosed multiple myeloma patients, regardless of transplant eligibility [1][2][3] Group 1: Study Findings - In the Phase 3 PERSEUS study, over half of the patients maintained MRD negativity for 24 months or longer with the DARZALEX FASPRO® regimen [1][2] - The addition of DARZALEX FASPRO® to the standard treatment regimen (bortezomib, lenalidomide, and dexamethasone) resulted in a 55.8% sustained MRD negativity rate at the 10⁻⁵ threshold compared to 22.6% with the standard regimen alone [2][4] - The Phase 3 CEPHEUS study showed a 60% overall MRD negativity rate at the 10⁻⁵ threshold in transplant-ineligible patients, indicating significant treatment benefits across different patient populations [1][3] Group 2: Long-term Outcomes - At a median follow-up of 47.5 months, the PFS rate was 95.3% at 48 months for patients receiving the DARZALEX FASPRO® regimen, highlighting its effectiveness in delaying disease progression [2] - The study results indicated that 69% of patients treated with the DARZALEX FASPRO® regimen remained progression-free at 54 months, compared to 48% with the standard regimen [4][5] - The overall survival (OS) favored the DARZALEX FASPRO® group, with a hazard ratio of 0.66, suggesting a potential survival benefit [4] Group 3: Safety and Efficacy - The safety profiles of DARZALEX FASPRO® in the PERSEUS and CEPHEUS studies were consistent with previously known safety data, indicating a manageable safety profile [5] - The studies included diverse patient populations, including those considered high-risk for cytogenetic abnormalities, reinforcing the broad applicability of DARZALEX FASPRO® in treating multiple myeloma [3][5] - The consistent results across different studies support the role of DARZALEX FASPRO® as a cornerstone of frontline therapy for multiple myeloma [5]